

info medica

Medical Education & Information

Certificata ISO 9001:2008 - IQNet - SGS n.n. CH-22441
per la "Progettazione ed erogazione di formazione e informazione medico-scientifica"
Provider ECM n. 3 (accreditamento standard)

Autocertificazione conflitto di interessi

Il sottoscritto Prof. Francesco Lo Coco, nato a Palermo il 31/10/1955, residente in via Catone n. 34, 00192 Roma, Cod. Fisc. LCCFNC55R30G273P, in qualità di:

Resp. scientifico ed ECM del programma FAD BLOOD ONLINE 2017-18 (www.bloodonline.it);


ai sensi dell'art. 3.3 sul Conflitto di Interessi, pag. 18,19 dell'Accordo Stato-Regione del 19 aprile 2012, per conto del Provider Infomedica (n. 3 - accreditamento standard)

DICHIARA

che negli ultimi due anni ha avuto i seguenti rapporti anche di finanziamento con soggetti portatori di interessi commerciali in campo sanitario: TEVA, NOVARTIS, LUNDBECK

Roma, 22 aprile 2017

In fede,



Prof. Francesco Lo Coco

Curriculum Vitae

Name Francesco Lo-Coco	Position Title Full Professor of Hematology
----------------------------------	---

Birthdate: 10/30/1955
Birthplace: Palermo, Italy
Citizenship: Italian
Address: Via Catone 34, 00192 Rome, Italy

Education/Training

Institution and Location	Degree	Year Conferred	Field of Study
University of Pisa , Italy	MD	1974-1981	Medicine
University La Sapienza, Rome, Italy	Specialist Degree	1982-1985	Hematology
Columbia University, New York, USA	Research Fellowship	1992-1994	Pathology

Professional Experience

Professional positions

1987- 2002	University La Sapienza, Rome-Italy; Dept. of Hematology, Head Molecular Biology Laboratory.
1993- 2002	University La Sapienza, Rome-Italy; Senior Staff Member, Hematology Section
2002- 2005	University Tor Vergata, Rome-Italy; Associate Professor of Hematology
2005-to date	University Tor Vergata, Rome-Italy; Full Professor of Hematology

Honors and Awards

- 1992:** International Prize G. Di Guglielmo, awarded by the Accademia Nazionale dei Lincei (Italy)
2009: S. Goshe Memorial Oration, Institute of Hematology, Medical College, Calcutta (India)
2010 A. Lagana Prize for the fight against leukemia, Latina (Italy)
2013 Commendatore al Merito della Repubblica Italiana
2014 2nd Cao and Galanello Memorial Lecture, Palermo (Italy)
2014 Sapio Award for Italian Research (Health section)
2015 Tata Memorial Center Oration, Mumbai (India)
2016 G. Venosta Prize, AIRC (Italy)
2017 P. Stryckmans Memorial Lecture (Belgian Society of Hematology)

Editorial Board of International Journals

- 2010-2013 Journal of Clinical Oncology (Editorial Board Member)
 1994-present Haematologica (Editorial Board Member)
 1996-2013 Leukemia (Editorial Board Member)
 From 1990: Reviewer for the journals: Blood, Lancet, Lancet Oncology, NEJM, J Clin Oncol, Cancer Research, Leukemia, Cancer, Annals of Oncology, Haematologica, Cancer, Acta Haematologica, Leukemia & Lymphoma, Bone Marrow Transplantation.

Consultant for Public Institutions and International Scientific Organizations (evaluation of research projects, and CV for promotions)

- 1997-2001: Italian National Institute of Health (revision projects)
 from 2002: Ministry of Health (targeted research projects)
 from 2006: AIFA (expert for experiments in oncohematology)
 1996: Dutch Cancer Society (NL)
 1996: A.I.L. (Associazione Italiana contro la Leucemia)
 1994-2002: AIRC-FIRC. (Associazione e Fondazione Italiana Ricerca sul Cancro)
 1998: Catholic University of Leuven (NL)
 2002: Czech Cancer Society, Czech Republic
 2002: Leukaemia Research Fund (UK)
 2008: Medical Research Council (UK)
 2008-2010: Center for Translational Molecular Medicine (NL)
 2011: Memorial Sloan-Kettering Cancer Center (USA)
 2009-2012: National Cancer Research Institute, UK
 2010-2014: Leukemia & Lymphoma Research Foundation (UK)
 2014-2016: Instituto de Salud Carlos III (Ministry of Health, Spain)

Positions in national and international scientific societies :

- 2000-2002: President of the Italian Society of Experimental Hematology (SIES)
 2008-2013: Chairman of the Education Committee of European Hematology Association (EHA)
 2008-2012: Member of International Members Committee, American Society of Hematology (ASH)
 2012-2015: Member of the Nominating Committee of the American Society of Hematology (ASH)

Selected Peer-Reviewed Publications

- 1) Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. **Lancet** 340: 1437,1992.
- 2) Lo Coco F, Pelicci PG, D'Adamo F et al. Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangement. **Blood** 82: 606,1993.
- 3) Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc-finger encoding gene, BCL-6 in diffuse large-cell lymphoma. **Science** 262: 747,1993.
- 4) Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL-6 gene in diffuse largecell non-Hodgkin's lymphoma **Blood** 83: 1757, 1994.
- 5) Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A, Ladany M, Jhanwar S, Dalla-Favera R, Chaganti R SK. Rearrangement of the BCL-6 gene as a prognostic marker in diffuse large-cell lymphoma. **New England Journal of Medicine** 331:74, 1994.
- 6) Mandelli F, Diverio D, Awisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Muus P, Willemze R, Jehn U, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. **Blood** 90:1014,1 997.
- 7) Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Mertinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F. Early detection of relapse by prospective RT-PCR analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. **Blood** 92:784, 1998
- 8) Di Croce L, Raker VA, Corcaro M, Fazi F, Fanelli M, Fuks F, Lo Coco F, et al. Methyltransferase recruitment to target promoters as a mechanism of DNA hypermethylation by an oncogenic transcription factor. **Science** 295: 1079,2002.

- 9) Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Venditti A, Tafuri A, Mandelli F. Gentuzumab ozogamicin ("mylotarg") as a single agent for molecularly relapsed acute promyelocytic leukemia. **Blood** 104:199, 2004.
- 10) Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF. Cytoplasmic Nucleophosmin (NPM) Identifies a Subtype of Acute Myelogenous Leukemia With A Normal Karyotype and NPM Gene Mutations. **New England Journal of Medicine** 352:254,2005.
- 11) Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JA, Osheroff N, Amadori S, Felix CA, Voso MT, Sperr WR, Esteve J, Sanz MA, Grimwade D, Lo-Coco F. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. **Blood** 2008 Oct 15;112(8):3383-90.
- 12) Lo-Coco F, Avvisati G, Paoloni F et al. for the Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. **Blood** 116:3171, 2010.
- 13) Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, Ottone T, Consalvo MI, Lavorgna S, Bulian P, Ammatuna E, Angelini DF, Diamantini A, Campagna S, Ottaviani L, Sarlo C, Gattei V, Del Poeta G, Arcese W, Amadori S, Lo-Coco F, Venditti A. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. **Blood** 116:2295, 2010
- 14) Lo-Coco F, Ferrara F, Amadori S, Annelbaum FB, Brühner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naos I, Niederwieser D, Ossenkoppele J, Sanz MA, Schanz J, Schmeck C, Schmitt B, Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. **Blood** 115:453, 2010
- 15) Lo-Coco F, Avvisati G, Vignetti M et al. Arsenic trioxide and retinoic acid for acute promyelocytic leukemia. **New England Journal of Medicine** 368: 111-121, 2013.
- 16) Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. **J Clin Oncol**. 2014;32(30):3406-12.
- 17) Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, Bardi M, Gargano F, Maurillo L, Divona M, Noguera NI, Consalvo MI, Borsellino G, Bernardi G, Amadori S, Venditti A, Battistini L, Lo-Coco F. A leukemia-associated CD34/CD123/CD25/CD99 immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. **Clinical Cancer Research**;21(17):3977-85, 2015.
- 18) Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. **Journal of Clinical Oncology** pii: JCO671982, 2016
- 19) Lo-Coco F, Di Donato L, Schlenk RF. Targeted therapy alone for acute promyelocytic leukemia. **New England Journal of Medicine** 374(12):1197-8, 2016.

20) Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorogna S, Alfonso V, Paoloni F, Piciocchi A, Avvisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco E. PML-RARA kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukemia treated with ATRA and ATO or ATRA and chemotherapy. **Leukemia** 2016 May 20. doi: 10.1038/leu.2016.122.

Rome, March 20, 2017

francesco Lo Coco